Milestone Pharmaceuticals Inc. MIST
- Market cap
- $99.0M
- P/E
- 0.0×
Follow MIST
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | 12.36 | 1.69 | 5.09 | 3.39 | 1.62 | 1.12 | 0.63 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | 27.95 | 23.25 | 9.03 | 9.85 | 4.49 | 2.75 | 3.06 |
High Price
|
|||
| — | — | 23 | 30 | 28 | 29 | 39 | 47 | 33 | 38 |
Employees
|
|||
| — | — | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | 15 | 5 | 1 | — | 2 |
Revenue
|
|||
| — | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | — | 100.00% |
Gross Margin
|
|||
| — | (8) | (23) | (55) | (50) | (43) | (58) | (60) | (42) | (63) |
EBT
|
|||
| — | 0.00% | 0.00% | 0.00% | 0.00% | (285.69%) | (1,167.76%) | (5,968.50%) | 0.00% | (4,078.78%) |
EBT Margin
|
|||
| — | (8) | (23) | (55) | (50) | (43) | (58) | (60) | (42) | (63) |
Net Income
|
|||
| — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Depreciation
|
|||
| — | 0.00 | 0.00 | 0.00 | 0.00 | 0.36 | 0.12 | 0.02 | 0.00 | 0.02 |
Revenue/Sh
|
|||
| — | (34.15) | (72.63) | (3.50) | (1.70) | (1.02) | (1.38) | (1.39) | (0.67) | (0.75) |
Earnings/Sh
|
|||
| — | (34.00) | (65.93) | (3.24) | (1.73) | (0.79) | (1.24) | (1.08) | (0.46) | (0.58) |
Cash Flow/Sh
|
|||
| — | (0.15) | (0.02) | (0.03) | 0.00 | 0.00 | (0.01) | 0.00 | 0.00 | 0.00 |
Capex/Sh
|
|||
| — | (34.16) | (65.95) | (3.27) | (1.73) | (0.79) | (1.24) | (1.08) | (0.46) | (0.59) |
Free CF/Sh
|
|||
| — | (139.86) | (172.96) | 7.28 | 4.88 | 2.69 | 1.56 | 0.39 | 0.21 | 0.50 |
Book Value/Sh
|
|||
| — | 0 | 0 | 16 | 29 | 42 | 42 | 43 | 62 | 84 |
Shares
|
|||
| — | — | — | — | — | 0.00 | 0.00 | 0.00 | — | 0.00 |
PE Ratio
|
|||
| — | — | — | — | — | 0.00 | 0.00 | 3.68 | — | 8.07 |
PS Ratio
|
|||
| — | — | — | — | — | 2.43 | 2.59 | 4.61 | — | 4.06 |
PB Ratio
|
|||
| — | — | — | — | — | 0.00 | 0.00 | 2.91 | — | 5.75 |
EV/Sales
|
|||
| — | — | — | — | — | (4.77) | (2.07) | (1.31) | — | (2.45) |
EV/FCF
|
|||
| — | (8) | (21) | (51) | (51) | (33) | (52) | (46) | (29) | (49) |
Op' Cash Flow
|
|||
| — | 0 | 0 | 0 | — | — | 0 | 0 | 0 | 0 |
Capex
|
|||
| — | (8) | (21) | (52) | (51) | (33) | (53) | (47) | (29) | (49) |
FCF
|
|||
| — | 26 | 84 | 114 | 143 | 112 | 66 | 66 | 66 | 98 |
Working Cap'
|
|||
| — | — | — | 0 | 1 | 0 | 2 | 50 | 53 | 57 |
Total Debt
|
|||
| — | (27) | (86) | (120) | (142) | (114) | (63) | (16) | (16) | (49) |
Net Debt
|
|||
| — | (33) | (55) | 115 | 143 | 113 | 66 | 17 | 13 | 42 |
Sh' Equity
|
|||
| — | (13.98%) | (40.09%) | (52.22%) | (36.55%) | (31.76%) | (60.09%) | (79.73%) | (55.09%) | (66.71%) |
ROA
|
|||
| — | 0.00% | 0.00% | 0.00% | (2,105.90%) | 0.00% | (991.65%) | (7,071.53%) | 0.00% | 0.00% |
ROIC
|
|||
| — | 18.31% | 52.50% | (185.00%) | (38.73%) | (33.52%) | (65.26%) | (143.61%) | (277.55%) | (229.65%) |
ROE
|
|||
Milestone Pharmaceuticals Inc. peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| CRDF Cardiff Oncology, Inc. | $99.6M | 0.0× | Compare |
| NRXS Neuraxis, Inc. | $97.3M | 0.0× | Compare |
| PMVP PMV Pharmaceuticals, Inc. | $100.8M | 0.0× | Compare |
| ANIX ANIXA BIOSCIENCES INC | $96.6M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| CLLS Cellectis S.A. | $103.4M | 0.0× | Compare |
| SEER Seer, Inc. | $103.6M | 0.0× | Compare |
| PMN Promis Neurosciences | $103.8M | 0.0× | Compare |
| VXRT VAXART, INC. | $92.4M | 2.8× | Compare |
Milestone Pharmaceuticals Inc. (MIST) key facts
- Milestone Pharmaceuticals Inc. (MIST) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- Milestone Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 million, up 54.6% from fiscal 2023.
- Milestone Pharmaceuticals Inc. reported a net loss of $63.1 million, or a loss of $0.75 per share, for fiscal 2025.
- As of September 25, 2026, MIST traded at $0.79, a market capitalization of $99.0 million.
- Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 20.7× sales.
- Return on equity was −229.7% and debt-to-equity 3.25.
Milestone Pharmaceuticals Inc. (MIST) Latest News
24 Sep
Montreal Heart Institute enrolled its first patient in Milestone's ReVeRA-301 Phase 3 trial evaluating etripamil nasal spray for AFib-RVR, expanding the multinational study into Canada with a target of about 150 treated events. ReVeRA-301 uses the same 70 mg repeat-dose regimen approved in the US for PSVT under CARDAMYST, and participants self-administer at home in a medically unsupervised setting. The primary endpoint is reduction in ventricular rate within 30 minutes, with a key secondary endpoint of patient-reported symptom improvement. The Canadian site joins the US and other centers, signaling ongoing momentum in global enrollment after the first US patient. Milestone is pursuing a single-study sNDA for AFib-RVR based on ReVeRA-301 data. CARDAMYST is FDA-approved for PSVT; etripamil is in Phase 3 for AFib-RVR in adults. Progress in a pivotal Phase 3 AFib-RVR trial with Canada expansion could materially impact regulatory timing and potential commercial opportunity for etripamil.
3 Sep
Milestone Pharmaceuticals receives NMPA approval for Etripamil Nasal Spray to treat PSVT in China, marking the first regulatory approval of the drug outside the United States. China approval of etripamil opens significant new market for Milestone's core PSVT treatment.
21 Aug
Milestone Pharmaceuticals shares rise after first patient enters Phase 3 AFib trial. Phase 3 trial start advances core drug pipeline and drives positive stock reaction for Milestone Pharmaceuticals.
Milestone Pharmaceuticals initiates pivotal Phase 3 trial of etripamil nasal spray for self-administered treatment of atrial fibrillation with rapid ventricular rate. Pivotal Phase 3 trial start advances etripamil development with potential to alter company trajectory through new product approval.
12 Aug
Milestone Pharmaceuticals Inc. reported Q2 2026 financial results and strategic updates during its earnings call. Earnings call delivers financial metrics and guidance with moderate effect on near-term valuation and sentiment.
Milestone Pharmaceuticals Inc. (MIST) held its Q2 earnings call covering financial results, operational updates, and forward outlook. Q2 earnings call delivers financial and strategic updates that can shift near-term investor views but rarely transform long-term trajectory alone.
Milestone Pharmaceuticals Inc. reported a Q2 loss and missed revenue estimates. Q2 loss and revenue shortfall signals weaker financial performance likely to pressure near-term stock sentiment.
Milestone Pharmaceuticals Inc. (MIST) shares declined after missing Q2 earnings expectations. Q2 earnings miss triggered share price drop and affects near-term financial perception.
Milestone Pharmaceuticals Inc. reported second quarter 2026 financial results and issued a corporate update. Quarterly earnings releases typically produce moderate stock movement from reported numbers and any forward guidance.
1 Jun
Milestone Pharmaceuticals Inc. (MIST) released its Q1 2026 earnings transcript covering financial results, operational updates, and outlook. Q1 2026 earnings transcript delivers financial metrics and guidance that directly shape near-term stock trajectory and investor positioning.
15 May
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) outlines its strategic path to profitability, highlighting key milestones, financial improvements, and operational efficiencies expected to drive future growth and positive market performance. Detailing a path to profitability involves major strategic moves that could significantly enhance financial trajectory and investor sentiment.
13 May
Milestone Pharmaceuticals Inc. (MIST) Q1 2026 earnings call summary covers quarterly financial results, operational updates, pipeline progress, and forward guidance. Q1 2026 earnings summary details financial performance and strategic outlook, poised to significantly sway investor sentiment and market trajectory.
Milestone Pharmaceuticals Inc. (MIST) Q1 2026 earnings call highlights strategic advances amid challenges. Strategic advances in Q1 2026 earnings call signal major moves that could alter MIST's trajectory and investor sentiment.
Milestone Pharmaceuticals released the complete transcript of its Q1 2026 earnings call, covering financial results, operational updates, and future outlook. Q1 2026 earnings call transcript details financial performance, strategic initiatives, and guidance that could significantly sway investor sentiment and stock trajectory.
Milestone Pharmaceuticals Inc. (MIST) shares plunged after CARDAMYST revenue missed expectations. CARDAMYST revenue miss triggered sharp share plunge, significantly harming financial performance and investor sentiment.
Milestone Pharmaceuticals released Q1 earnings call highlights, detailing financial results, pipeline progress on etripamil for PSVT, regulatory updates, and forward guidance. Q1 earnings highlights cover financial performance and pipeline updates with moderate influence on investor sentiment and stock trajectory.
Milestone Pharmaceuticals Inc. (MIST) announced first quarter 2026 financial results and provided a corporate update. Quarterly financial results and corporate update affect key financial performance metrics and investor sentiment.
10 Apr
Milestone Pharmaceuticals launches RESET-PSVT Registry to generate real-world evidence on CARDAMYST (etripamil) nasal spray for patients with paroxysmal supraventricular tachycardia (PSVT). Real-world evidence from the registry could moderately enhance CARDAMYST's market positioning and adoption for PSVT.
31 Mar
Milestone Pharmaceuticals Inc. (MIST) announces CARDAMYST™ (etripamil) nasal spray is now available on Express Scripts Commercial National Formularies. Inclusion on Express Scripts formularies expands reimbursement access and sales potential for CARDAMYST, significantly impacting MIST's revenue trajectory.
20 Mar
Milestone Pharmaceuticals Inc. (MIST) Q4 2025 earnings call highlights strategic advances amid challenges. Strategic advances in Q4 2025 earnings call signal major shifts in competitive positioning and investor sentiment for MIST.
Milestone Pharmaceuticals reported fourth quarter and full-year 2025 financial results and provided an update on the commercial launch of CARDAMYST™ (etripamil) nasal spray for paroxysmal supraventricular tachycardia (PSVT) treatment. Commercial launch update for flagship nasal spray product alongside financial results represents a major milestone likely to enhance market position and investor sentiment.
Milestone Pharmaceuticals Inc. (MIST) shared Q4 earnings call highlights, covering financial results, etripamil development updates, regulatory progress, and 2024 outlook. Q4 earnings highlights detail financials and pipeline advancements with moderate influence on stock performance and investor outlook.
Milestone Pharmaceuticals Inc. (MIST) released Q4 earnings snapshot detailing financial results. Q4 earnings snapshot impacts financial performance and investor sentiment moderately.
16 Mar
Milestone Pharmaceuticals to present data on CARDAMYST™ (etripamil) nasal spray at the 2026 American College of Cardiology Annual Scientific Session. Data presentation at a leading cardiology conference on the company's lead product could significantly enhance investor sentiment and competitive positioning.
10 Feb
Milestone Pharmaceuticals Inc. has appointed David Sandoval as General Counsel and Chief Compliance Officer. Sandoval brings extensive legal and compliance experience, having previously held senior roles in various pharmaceutical companies. His appointment is expected to enhance Milestone's legal framework and compliance strategies as the company advances its pipeline of cardiovascular therapies. The appointment of a seasoned legal professional is likely to positively influence compliance and operational efficiency, impacting the company's overall performance.
27 Jan
Milestone Pharmaceuticals Inc. (MIST) has received a rating upgrade to 'Strong Buy' from analysts, reflecting increased confidence in the company's growth potential and product pipeline. This upgrade is expected to positively influence investor sentiment and market performance, as MIST continues to advance its clinical programs and strategic initiatives. The rating upgrade indicates significant positive sentiment and potential for future performance improvements.
Milestone Pharmaceuticals Inc. has announced the U.S. availability of Cardamyst, a novel treatment for acute migraine. This product is designed to provide rapid relief and is expected to enhance the company's portfolio in the migraine treatment market. The launch follows successful clinical trials demonstrating Cardamyst's efficacy and safety. Milestone aims to address the significant unmet needs of migraine sufferers with this innovative therapy. The launch of Cardamyst represents a significant strategic move that could enhance Milestone's market position and investor sentiment.
26 Jan
Milestone Pharmaceuticals Inc. has announced the U.S. availability of CARDAMYST™ (etripamil) nasal spray, marking it as the first and only FDA-approved self-administered treatment for adults suffering from Paroxysmal Supraventricular Tachycardia (PSVT). This innovative treatment aims to provide patients with a convenient option for managing their condition. The launch of CARDAMYST™ represents a significant advancement in treatment options for PSVT, likely enhancing the company's market position and investor sentiment.
7 Jan
Milestone Pharmaceuticals Inc. announced that the European Medicines Agency (EMA) has accepted its Marketing Authorization Application (MAA) for etripamil nasal spray, a treatment for acute episodes of paroxysmal supraventricular tachycardia (PSVT). This acceptance marks a significant step in the regulatory process for the product, which aims to provide a non-invasive option for patients experiencing PSVT episodes. The company is now positioned to advance its commercialization efforts in Europe pending the outcome of the review. Acceptance of the MAA by the EMA is a significant regulatory milestone that could enhance market positioning and investor sentiment for Milestone Pharmaceuticals.
6 Jan
Milestone Pharmaceuticals Inc. announced that the European Medicines Agency has accepted its Marketing Authorization Application for Etripamil Nasal Spray, a treatment for paroxysmal supraventricular tachycardia (PSVT). This acceptance marks a significant step towards potential approval and commercialization of the product in Europe, which could enhance the company's market presence and revenue streams. Acceptance of the Marketing Authorization Application is a significant regulatory milestone that could lead to product launch and increased market share.